Hepatobiliary phase in cirrhotic patients with different Model for End-stage Liver Disease score: comparison of the performance of gadoxetic acid to gadobenate dimeglumine

6533b86efe1ef96bd12cb539

RESEARCH PRODUCT

Hepatobiliary phase in cirrhotic patients with different Model for End-stage Liver Disease score: comparison of the performance of gadoxetic acid to gadobenate dimeglumine

Claudia Khouri Chalouhi Federica Vernuccio Angelo Vanzulli Francesca Rini Bruno Tuscano Piergiorgio Duca Giuseppe Brancatelli

subject

Liver Cirrhosis Adult Male Gadolinium DTPA Gadoxetic acid medicine.medical_specialty Liver Cirrhosi Contrast Media Sensitivity and Specificity Severity of Illness Index 030218 nuclear medicine & medical imaging Gadobenic acid 03 medical and health sciences Liver disease Young Adult 0302 clinical medicine Model for End-Stage Liver Disease Meglumine Gadobenic acid Retrospective Studie medicine Gadolinium ethoxybenzyl DTPA Organometallic Compounds Humans Radiology Nuclear Medicine and imaging Retrospective Studies Neuroradiology Aged Aged 80 and over Cross-Sectional Studie medicine.diagnostic_test Meglumine business.industry Magnetic resonance imaging General Medicine Odds ratio Middle Aged medicine.disease Magnetic Resonance Imaging Cross-Sectional Studies 030220 oncology & carcinogenesis Female Radiology Nuclear medicine business medicine.drug Human

description

The purpose of this study was to compare the performance of gadobenate dimeglumine–enhanced MRI and gadoxetic acid–enhanced MRI in the hepatobiliary phase (HBP) in cirrhotic patients with different degrees of liver dysfunction. In this retrospective cross-sectional study, we analyzed the unenhanced phase and the HBP of 131 gadobenate dimeglumine–enhanced MRI examinations (gadobenate dimeglumine group) and 127 gadoxetic acid–enhanced MRI examinations (gadoxetic acid group) performed in 249 cirrhotic patients (181 men and 68 women; mean age, 64.8 years) from August 2011 to April 2017. For each MRI, the contrast enhancement index of the liver parenchyma was calculated and correlated to the Model For End-Stage Liver Disease (MELD) score (multiple linear regression analysis). A qualitative analysis of the adequacy of the HBP, adjusted for the MELD score (logistic regression analysis), was performed. The contrast enhancement index was inversely related (r = − 0.013) with MELD score in both gadoxetic acid and gadobenate dimeglumine group. At the same MELD score, the contrast enhancement index in the gadoxetic acid group was increased by a factor of 0.23 compared to the gadobenate dimeglumine group (p 10, if the hepatobiliary phase is clinically indicated. • In patients with high MELD score (> 15), the administration of the hepatobiliary agent could be useless; even though, if it is clinically indicated, we recommend to use gadoxetic acid given the higher probability of obtaining clinically relevant information.

year	journal	country	edition	language
2018-12-13

10.1007/s00330-018-5884-2 http://hdl.handle.net/10447/366862